Mechanisms of Drug Interactions

  • Angela D. M. Kashuba
  • Joseph S. BertinoJr.
Part of the Infectious Disease book series (ID)


One hundred and fifty million outpatient prescriptions for antibiotics are dispensed each year in the United States (1). In institutional settings, 25–35% of hospitalized patients receive antibiotic treatment for active infections or to prevent infections (2). Given that antibiotics represent global sales of approximately $20 billion of a $370 billion pharmaceutical market, one can assume that many patients who are prescribed antibiotics are also receiving other agents (3). Therefore, the potential for drug interactions is significant.


Drug Interaction Antimicrob Agent Human Hepatocyte Cytochrome P450 Enzyme Grapefruit Juice 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Levy SB. The challenge of antibiotic resistance. Sci Am 1998; 278: 46–53.PubMedCrossRefGoogle Scholar
  2. 2.
    U.S. Congress, Office of Technology Assessment. Impacts of Antibiotic Resistant Bacteria; OTA-H 629. Washington, DC: US Government Printing Office, September 1995.Google Scholar
  3. 3.
    IMS America web site. June 1999.Google Scholar
  4. 4.
    Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998; 23: 403–416.PubMedCrossRefGoogle Scholar
  5. 5.
    Lin JH, Lu AY Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361–390.PubMedCrossRefGoogle Scholar
  6. 6.
    Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psych 1998; 59 (suppl 15): 19–27.Google Scholar
  7. 7.
    Shannon M. Drug-drug interactions and the cytochrome P450 system: an update. Ped Emergency Care 1997; 13: 350–353.CrossRefGoogle Scholar
  8. 8.
    Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv Pharmacol 1997; 43: 7–35.PubMedCrossRefGoogle Scholar
  9. 9.
    Ritschel WA. (ed.). Handbook of Basic Pharmacokinetics. 4th ed. Hamilton, IL: Drug Intelligence Publications.Google Scholar
  10. 10.
    Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404–434.PubMedCrossRefGoogle Scholar
  11. 11.
    Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs; an update. Clin Pharmacokinet 1990; 18: 210–219.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992; 14: 773–779.PubMedCrossRefGoogle Scholar
  13. 13.
    Horowitz HW, Jorde UP, Wormser GP. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis. Lancet 1992; 339: 747.PubMedCrossRefGoogle Scholar
  14. 14.
    Moreno F, Hardin TC, Rinaldi MG, et al. Itraconazole-didanosine excipient interaction. JAMA 1993; 269: 1508.PubMedCrossRefGoogle Scholar
  15. 15.
    Metroka CE, McMechan MF, Andrada R, et al. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med 1991; 325: 737.PubMedGoogle Scholar
  16. 16.
    Fisher RS, Sher DJ, Donahue D, et al. Regional differences in gastric acidity and antacid distribution: is a single pH electrode sufficient? Am J Gastroenterol 1997; 92: 263–270.PubMedGoogle Scholar
  17. 17.
    Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing duodenal ulcers? Gastroenterology 1990; 99: 345–351.PubMedGoogle Scholar
  18. 18.
    Kanda Y, Kami M, Matsuyama T, et al. Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole. Hematol Oncol 1998; 16: 33–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54: 159–161.PubMedCrossRefGoogle Scholar
  20. 20.
    Chin TW, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995; 39: 1671–1675.PubMedCrossRefGoogle Scholar
  21. 21.
    Hansten PD. Drug interactions with antisecretory agents. Aliment Pharmacol Ther 1991; 5 (suppl 1): 121–128.PubMedGoogle Scholar
  22. 22.
    Somogyi A, Muirhead M. Pharmacokinetic interactions of cimetidine 1987. Clin Pharmacokinet 1987; 12: 321–366.CrossRefGoogle Scholar
  23. 23.
    Sadowski DC. Drug interactions with antacids. Mechanisms and clinical significance. Drug Safefy 1994; 11: 395–407.CrossRefGoogle Scholar
  24. 24.
    Knupp CA, Barbhaiya RH. A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic. Biopharmaceut Drug Disp 1997; 18: 65–77.CrossRefGoogle Scholar
  25. 25.
    Polk RE. Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 1989; 87: 76S - 81S.PubMedCrossRefGoogle Scholar
  26. 26.
    Sahai J, Gallicano K, Oliveras L, et al. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993; 53: 292–297.PubMedCrossRefGoogle Scholar
  27. 27.
    Lomaestro BM, Bailie GR. Quinolone-cation interactions: a review. DICP 1991; 25: 1249–1258.PubMedGoogle Scholar
  28. 28.
    Yuk JH, Nightingale CH, Sweeney KR, et al. Relative bioavailability in healthy volunteers of ciprofloxacin administered through nasogastric tube with or without enteral feeding. Antimicrob Agents Chemother 1989; 33: 1118–1120.PubMedCrossRefGoogle Scholar
  29. 29.
    Yuk JH, Nightingale CH, Quintiliani R, et al. Absorption of ciprofloxacin administered through a nasogastric or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. Diag Micro Infect Dis 1990; 13: 99–102.CrossRefGoogle Scholar
  30. 30.
    Neuvonen PJ, Gothon G, Hackman R, et al. Interference of iron with the absorption of tetracyclines in man. Br Med J 1970; 4: 532–534.PubMedCrossRefGoogle Scholar
  31. 31.
    Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol 1985; 12 (2 Pt 1): 308–312.Google Scholar
  32. 32.
    Campbell NR, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 1991; 31: 251–255.PubMedCrossRefGoogle Scholar
  33. 33.
    Questran product monograph, Cholestyramine for oral suspension. BMS. Product Monograph. September 1993.Google Scholar
  34. 34.
    Parsons RL, Paddock GM. Absorption of two antibacterial drugs, cephalexin and cotrimoxazole, in malabsorption syndromes. J Antimicrob Chemother 1975; 1 (suppl): 59–67.PubMedCrossRefGoogle Scholar
  35. 35.
    Fraga Fuentes MD, Garcia Diaz B, de Juana Velasco P, et al. Influence of foods on the absorption of antimicrobial agents. Nutricion Hospitalaria 1997; 12: 277–288.Google Scholar
  36. 36.
    Tonini M. Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacol Res 1996; 33 (4–5): 217–226.PubMedCrossRefGoogle Scholar
  37. 37.
    Kedderis GL. Pharmacokinetics of drug interactions. Adv Pharmacol 1997; 43: 189–203.PubMedCrossRefGoogle Scholar
  38. 38.
    Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996; 13: 963–977.PubMedCrossRefGoogle Scholar
  39. 39.
    Zhang L, Brett CM, Giacomini KM. Role of organic cation transporters in drug absorption and elimination. Ann Rev Pharm Tox 1998; 38: 431–460.CrossRefGoogle Scholar
  40. 40.
    Saitoh H, Fujisaki H, Aungst BJ, et al. Restricted intestinal absorption of some betalactam antibiotics by an energy-dependent efflux system in rat intestine. Pharm Res 1997; 14: 645–649.PubMedCrossRefGoogle Scholar
  41. 41.
    Rabbaa L, Dautrey S, Colas-Linhart N, et al. Absorption of ofloxacin isomers in the rat small intestine. Antimicrob Agents Chemother 1997; 41: 2274–2277.PubMedGoogle Scholar
  42. 42.
    Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 1997; 14: 763–766.PubMedCrossRefGoogle Scholar
  43. 43.
    Delie F, Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. Crit Rev Ther Drug Carrier Syst 1997; 14: 221–286.PubMedCrossRefGoogle Scholar
  44. 44.
    Lu AY. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Met Disp 1998; 26: 1217–1222.Google Scholar
  45. 45.
    Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Met Disp 1999; 27: 161–166.Google Scholar
  46. 46.
    Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129–134.PubMedCrossRefGoogle Scholar
  47. 47.
    Schuetz EG, Beck WT, Schuetz JD. Modulation and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996; 49: 311–318.PubMedGoogle Scholar
  48. 48.
    Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet 1997; 32: 210–258.PubMedCrossRefGoogle Scholar
  49. 49.
    Bonkovsky HL, Hauri HP, Marti U, et al. Cytochrome P450 of small intestinal epithelial cells. Gastroenterology 1985; 88: 458–467.PubMedGoogle Scholar
  50. 50.
    Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26: 144–160.PubMedCrossRefGoogle Scholar
  51. 51.
    Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552–1562.PubMedGoogle Scholar
  52. 52.
    Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Tox 1998; 38: 389–430.CrossRefGoogle Scholar
  53. 53.
    Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871–1878.PubMedCrossRefGoogle Scholar
  54. 54.
    Thummel KE, O’Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491–502.PubMedCrossRefGoogle Scholar
  55. 55.
    Gibbs MA, Thummel KE, Shen DD, et al. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of K ; values and impact of CYP3A5 expression. Drug Met Disp 1999; 27: 180–187.Google Scholar
  56. 56.
    Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64: 133–143.PubMedCrossRefGoogle Scholar
  57. 57.
    Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2245–2253.CrossRefGoogle Scholar
  58. 58.
    Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Disp 1997; 25: 1228–1233.Google Scholar
  59. 59.
    Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 103–121.PubMedCrossRefGoogle Scholar
  60. 60.
    Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–28.PubMedCrossRefGoogle Scholar
  61. 61.
    Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion-pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997; 52: 139–145.PubMedCrossRefGoogle Scholar
  62. 62.
    Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51–58.PubMedCrossRefGoogle Scholar
  63. 63.
    Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998; 45: 355–359.PubMedCrossRefGoogle Scholar
  64. 64.
    Kawakami M, Suzuki K, Ishizuka T, et al. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther 1998; 36: 306–308.PubMedGoogle Scholar
  65. 65.
    Cheng KL, Nafziger AN, Peloquin CA, et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. Antimicrob Agents Chemother 1998; 42: 927–929.PubMedGoogle Scholar
  66. 66.
    Tsunoda SM, Velez RL, Greenblatt DJ. Ketoconazole inhibition of intestinal and hepatic cytochrome P450 3A4 (CYP3A4) activity using midazolam as an in vivo probe. Clin Pharmacol Ther 1999; 65: 172.CrossRefGoogle Scholar
  67. 67.
    Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453–464.PubMedCrossRefGoogle Scholar
  68. 68.
    Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218–3224.PubMedGoogle Scholar
  69. 69.
    Paine MF, Schmiedlin-Ren P, Watkins PB. Cytochrome P-450 lAl expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Disp 1999; 27: 360–364.Google Scholar
  70. 70.
    Stein WD. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997; 77: 545–590.PubMedGoogle Scholar
  71. 71.
    Lown KS, Fontana RJ, Schmiedlin-Ren P, et al. Interindividual variation in intestinal mdrl:lack of short term diet effects. Gastroenterology 1995; 108: A737.Google Scholar
  72. 72.
    Willie RT, Lown KS, Huszezo UR, et al. Short term effect of medications on CYP3A and P-glycoprotein expression in human intestinal mucosa. Gastroenterology 1997; 112 (suppl): A419.Google Scholar
  73. 73.
    Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123–128.PubMedCrossRefGoogle Scholar
  74. 74.
    Cormet-Boyaka E, Huneau JF, Mordrelle A, et al. Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother 1998; 42: 2607–2611.PubMedGoogle Scholar
  75. 75.
    Annaert P, Van Gelder J, Naesens L, et al. Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharm Res 1998; 15: 1168–1173.PubMedCrossRefGoogle Scholar
  76. 76.
    Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998; 15: 423–428.PubMedCrossRefGoogle Scholar
  77. 77.
    Srinivas RV, Middlemas D, Flynn P, et al. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998; 42: 3157–3162.PubMedGoogle Scholar
  78. 78.
    Kim AE, Dintaman JM, Waddell DS, et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 1439–1445.PubMedGoogle Scholar
  79. 79.
    Salphati L, Benet LZ. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998; 56: 308–313.PubMedCrossRefGoogle Scholar
  80. 80.
    Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998; 358: 289–294.PubMedCrossRefGoogle Scholar
  81. 81.
    Soldner A, Christians U, Susanto M, et al. Grapefruit juice activates P-glycoproteinmediated drug transport. Pharm Res 1999; 16: 478–485.PubMedCrossRefGoogle Scholar
  82. 82.
    Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Safety 1995; 12: 227–233.PubMedCrossRefGoogle Scholar
  83. 83.
    Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetics and therapeutic implications. Clin Pharmacokinet 1977; 2: 252.PubMedCrossRefGoogle Scholar
  84. 84.
    McElnay JC, D’Arcy PF. Protein binding displacement interactions and their clinical importance. Drugs 1983; 25: 495–513.PubMedCrossRefGoogle Scholar
  85. 85.
    Rowland M. Plasma protein binding and therapeutic drug monitoring. Ther Drug Monit 1980; 2: 29–37.PubMedCrossRefGoogle Scholar
  86. 86.
    Rolan PR. Plasma protein binding displacement interactions-why are they still regarded as clinically important? Br J Clin Pharmacol 1994; 37: 125–128.PubMedCrossRefGoogle Scholar
  87. 87.
    Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades des pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–2790.PubMedCrossRefGoogle Scholar
  88. 88.
    Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231–238.PubMedCrossRefGoogle Scholar
  89. 89.
    Pohjola-Sintonen S, Viitasalo M, Toivonen L, et al. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191–193.PubMedCrossRefGoogle Scholar
  90. 90.
    Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction, Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–1518.PubMedCrossRefGoogle Scholar
  91. 91.
    Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84–112.PubMedGoogle Scholar
  92. 92.
    Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42.PubMedCrossRefGoogle Scholar
  93. 93.
    Degtyarenko KN, Fâbiân P. (June 1999) Directory of P450-Containing Systems. http://www.icgeb.triestelt/p450/P450Nom_Full.html#Animalia.Google Scholar
  94. 94.
    Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Tox 1992; 22: 1–21.CrossRefGoogle Scholar
  95. 95.
    Smith G, Stubbins MJ, Harries LW, et al. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998; 28: 1129–1165.PubMedCrossRefGoogle Scholar
  96. 96.
    Pelkonen O, Maenpaa J, Taavitsainen P, et al. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998; 28: 1203–1253.PubMedCrossRefGoogle Scholar
  97. 97.
    Daly AK, Fairbrother KS, Smart J. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicol Lett 1998; 102, 103, 143–147.Google Scholar
  98. 98.
    Kroemer HK, Eichelbaum M. “It’s the genes, stupid.” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56: 2285–2298.PubMedCrossRefGoogle Scholar
  99. 99.
    Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413–580.PubMedCrossRefGoogle Scholar
  100. 100.
    Vanden Bossche H, Koymans L, Moereels H. P450 inhibitors of use in medical treatment:focus on mechanisms of action. Pharmacol Ther 1995; 67: 79–100.CrossRefGoogle Scholar
  101. 101.
    Murray M. Drug-mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol 1997; 24: 465–470.PubMedCrossRefGoogle Scholar
  102. 102.
    Babany G, Larrey D, Pessayre D. Macrolide antibiotics as inducers and inhibitors of cytochrome P-450 in experimental animals and man. In: Gibson GG. (ed.). Progress in Drug Metabolism. London: Taylor & Francis, 1988, pp. 61–98.Google Scholar
  103. 103.
    Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63–79.PubMedCrossRefGoogle Scholar
  104. 104.
    Gray MR, Tam YK. Pharmacokinetics of drugs that inactivate metabolic enzymes. J Pharmaceut Sci 1991; 80: 121–127.CrossRefGoogle Scholar
  105. 105.
    Wooles WR, Borzelleca JF. Prolongation of barbiturate sleeping time in mice by stimulation of the reticuloendothelial system (RES). J Reticuloendothel Soc 1966; 3: 41–47.PubMedGoogle Scholar
  106. 106.
    Leeson GA, Biedenbach SA, Chan KY, et al. Decrease in the activity of the drug-metabolizing enzymes of rat liver following the administration of tilorone hydrochloride. Drug Metab Disp 1976; 4: 232–238.Google Scholar
  107. 107.
    Trenholme GM, Williams RL, Rieckmann KH, et al. Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther 1976; 19: 459–467.PubMedGoogle Scholar
  108. 108.
    Chang KC, Bell TD, Lauer BA, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 1: 1132, 1133.Google Scholar
  109. 109.
    Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982; 69: 476–480.PubMedGoogle Scholar
  110. 110.
    Renton KW, Mannering GJ. Depression of the hepatic cytochrome P-450 mono-oxygenase system by administered tilorone (2,7-bis(2-(diethylamino)ethoxy)fluoren-9-one dihydrochloride). Drug Metab Disp 1976; 4: 223–231.Google Scholar
  111. 111.
    Sonne J, Dossing M, Loft S, et al. Antipyrine clearance in pneumonia. Clin Pharmacol Ther 1985; 37: 701–704.PubMedCrossRefGoogle Scholar
  112. 112.
    Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994; 94: 2209–2214.PubMedCrossRefGoogle Scholar
  113. 113.
    Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolize midazolam. Anaesthesia 1987; 42: 619–626.PubMedCrossRefGoogle Scholar
  114. 114.
    Brockmeyer NH, Barthel B, Mertins L, et al. Changes of antipyrine pharmacokinetics during influenza and after administration of interferon-alpha and -beta. Int J Clin Pharmacol Ther 1998; 36: 309–311.PubMedGoogle Scholar
  115. 115.
    Gidal BE, Reiss WG, Liao JS, et al. Changes in interleukin-6 concentrations following epilepsy surgery: potential influence on carbamazepine pharmacokinetics. Ann Pharmacother 1996; 30: 545, 546.Google Scholar
  116. 116.
    Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649–660.PubMedCrossRefGoogle Scholar
  117. 117.
    Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129–1188.PubMedCrossRefGoogle Scholar
  118. 118.
    Sewer MB, Morgan ET. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-lbeta and endotoxin in primary rat hepatocytes. Biochem Pharmacol 1997; 54: 729–737.PubMedCrossRefGoogle Scholar
  119. 119.
    Tinel M, Robin MA, Doostzadeh J, et al. The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. Gastroenterology 1995; 109: 1589–1599.PubMedCrossRefGoogle Scholar
  120. 120.
    Chen J, Nikolova-Karakashian M, Merrill AH. Jr, et al. Regulation of cytochrome P450 2C11 (CYP2C11) gene expression by interleukin-1, sphingomyelin hydrolysis, and ceramides in rat hepatocytes. J Biol Chem 1995;270:25, 233–25, 238.Google Scholar
  121. 121.
    Morgan ET, Thomas KB, Swanson R, et al. Selective suppression of cytochrome P-450 gene expression by interleukins 1 and 6 in rat liver. Biochim Biophys Acta 1994; 1219: 475–483.PubMedCrossRefGoogle Scholar
  122. 122.
    Wright K, Morgan ET. Regulation of cytochrome P4501IC12 expression by interleukin-1 alpha, interleukin-6, and dexamethasone. Mol Pharmacol 1991; 39: 468–474.PubMedGoogle Scholar
  123. 123.
    Abdel-Razzak Z, Corcos L, Fautrel A, et al. Interleukin-1 beta antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture. FEBS Lett 1995; 366 (2–3): 159–164.PubMedCrossRefGoogle Scholar
  124. 124.
    Fukuda Y, Ishida N, Noguchi T, et al. Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells. Biochem Biophys Res Comm 1992; 184: 960–965.PubMedCrossRefGoogle Scholar
  125. 125.
    Barker CW, Fagan JB, Pasco DS. Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J Biol Chem 1992; 267: 8050–8055.PubMedGoogle Scholar
  126. 126.
    Berthou F, Ratanasavanh D, Alix D, et al. Caffeine and theophylline metabolism in newborn and adult human hepatocytes; comparison with adult rat hepatocytes. Biochem Pharmacol 1988; 37: 3691–3700.PubMedCrossRefGoogle Scholar
  127. 127.
    Veronese ME, McManus ME, Laupattarakasem P, et al. Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P-450. Drug Metab Disp 1990; 18: 356–361.Google Scholar
  128. 128.
    Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996; 24: 48–57.PubMedCrossRefGoogle Scholar
  129. 129.
    Kurokohchi K, Matsuo Y, Yoneyama H, et al. Interleukin 2 induction of cytochrome P450-linked monooxygenase systems of rat liver microsomes. Biochem Pharmacol 1993; 45: 585–592.PubMedCrossRefGoogle Scholar
  130. 130.
    Cantoni L, Carelli M, Ghezzi P, et al. Mechanisms of interleukin-2-induced depression of hepatic cytochrome P-450 in mice. Eur J Pharmacol 1995; 292 (3–4): 257–263.PubMedGoogle Scholar
  131. 131.
    Ansher SS, Puri RK, Thompson WC, et al. The effects of interleukin 2 and alpha-interferon administration on hepatic drug metabolism in mice. Cancer Res 1992; 52: 262–266.PubMedGoogle Scholar
  132. 132.
    Craig PI, Williams SJ, Cantrill E, et al. Rat but not human interferons suppress hepatic oxidative drug metabolism in rats. Gastroenterology 1989; 97: 999–1004.PubMedGoogle Scholar
  133. 133.
    Pageaux GP, le Bricquir Y, Berthou F, et al. Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998; 10: 491–495.PubMedCrossRefGoogle Scholar
  134. 134.
    Okuno H, Kitao Y, Takasu M, et al. Depression of drug metabolizing activity in the human liver by interferon-alpha. Eur J Clin Pharmacol 1990; 39: 365–367.PubMedCrossRefGoogle Scholar
  135. 135.
    Okuno H, Takasu M, Kano H, et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993; 17: 65–69.PubMedCrossRefGoogle Scholar
  136. 136.
    Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986; 22: 610–612.PubMedCrossRefGoogle Scholar
  137. 137.
    Israel BC, Blouin RA, McIntyre W, et al. Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229–235.PubMedCrossRefGoogle Scholar
  138. 138.
    Piscitelli SC, Vogel S, Figg WD, et al. Alteration in indinavir clearance during interleukin2 infusions in patients infected with the human immunodeficiency virus. Pharmacotherapy 1998; 18: 1212–1216.PubMedGoogle Scholar
  139. 139.
    Elkahwaji J, Robin MA, Berson A, et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999; 57: 951–954.PubMedCrossRefGoogle Scholar
  140. 140.
    Kleman MI, Overvik E, Poellinger L, et al. Induction of cytochrome P4501 A isozymes by heterocyclic amines and other food-derived compounds. Princess Takamatsu Symp 1995; 23: 163–171.PubMedGoogle Scholar
  141. 141.
    Dogra SC, Whitelaw ML, May BK. Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers. Clin Exp Pharmacol Physiol 1998; 25: 1–9.PubMedCrossRefGoogle Scholar
  142. 142.
    Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016–1023.PubMedCrossRefGoogle Scholar
  143. 143.
    Patel M, Tang BK, Kalow W. Variability of acetaminophen metabolism in caucasians and orientals. Pharmacogenetics 1992; 2: 38–45.PubMedCrossRefGoogle Scholar
  144. 144.
    Weinshilboum R. Sulfotransferase pharmacogenetics. Pharmacol Ther 1990; 45: 93–107.PubMedCrossRefGoogle Scholar
  145. 145.
    Weinshilboum R. Methyltransferase pharmacogenetics. Pharmacol Ther 1989; 43: 77–90.PubMedCrossRefGoogle Scholar
  146. 146.
    Evans DA. N-Acetyltransferase. Pharmacol Ther 1989; 42: 157–234.PubMedCrossRefGoogle Scholar
  147. 147.
    Lennard MS. Genetically determined adverse drug reactions involving metabolism. Drug Safety 1993; 9: 60–77.PubMedCrossRefGoogle Scholar
  148. 148.
    Spielberg SP. N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996; 24: 509–519.PubMedGoogle Scholar
  149. 149.
    Park BK, Kitteringham NR. Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications. Xenobiotica 1990; 20: 1171–1185.PubMedCrossRefGoogle Scholar
  150. 150.
    Burchell B, McGurk K, Brierly CH, et al. UDP-glucuronosyltransferases. In: Guengerich FP. (ed.). Biotransformation, Vol 3, Comprehensive Toxicology. Oxford: Elsevier Science.Google Scholar
  151. 151.
    Abid A, Sabolovic N, Batt AM, et al. Induction of UDP-glucuronosyltransferases and cytochromes P450 in human hepatocytes. Cell Pharmacol 1994; 1: 257–262.Google Scholar
  152. 152.
    Burger DM, Meenhorst PL, ten Napel CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994; 8: 1683–1689.PubMedCrossRefGoogle Scholar
  153. 153.
    Hayes JD, McLeod R, Pulford DJ, et al. Regulation and activity of glutathione S-transferases. ISSX Proc 1996; 10: 12–18Google Scholar
  154. 154.
    Bonate PL, Reith K, Weir S. Drug interactions at the renal level: implications for drug development. Clin Pharmacokinet 1998; 34: 375–404.PubMedCrossRefGoogle Scholar
  155. 155.
    van Ginneken CA, Russel FG. Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 1989; 16: 38–54.PubMedCrossRefGoogle Scholar
  156. 156.
    Kirby WMM, DeMaine JB, Serrill WS. Pharmacokinetics of the cephalosporins in healthy volunteer and uremic patients. Postgrad Med J 1971; 47: 41–46.PubMedGoogle Scholar
  157. 157.
    Kampmann J, Molholm-Hansen J, Siersbaeck-Nielsen K, et al. Effect of some drugs on penicillin half-life in blood. Clin Pharmacol Ther 1972; 13: 516–519.PubMedGoogle Scholar
  158. 158.
    Prescott LF. Clinically important drug interactions. Drugs 1973; 5: 161–186.PubMedCrossRefGoogle Scholar
  159. 159.
    Chatton JY, Munafo A, Chave JP, et al. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol 1992; 34: 551–554.PubMedGoogle Scholar
  160. 160.
    Fletcher CV, Henry WK, Noormohamed SE, et al. The effect of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy 1995; 15: 701–708.PubMedGoogle Scholar
  161. 161.
    Ito T, Yano I, Tanaka K, et al. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther 1997; 282: 955–960.PubMedGoogle Scholar
  162. 162.
    Kaukonen KM, Olkkola KT, Neuvonen PJ. Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther 1997; 62: 510–517.PubMedCrossRefGoogle Scholar
  163. 163.
    Bendayan R, Georgis W, Rafi-Tari S. Interaction of 3’-azido-3’-deoxythymidine with the organic base transporter in a cultured renal epithelium. Pharmacotherapy 1995; 15: 338–344.PubMedGoogle Scholar
  164. 164.
    Sweeney KR, Hsyu PH, Statkevich P, et al. Renal disposition and drug interaction screening of (-)-2’-deoxy-3’-thiacytidine (3TC) in the isolated perfused rat kidney. Pharm Res 1995; 12: 1958–1963.PubMedCrossRefGoogle Scholar
  165. 165.
    Bendayan R. Renal drug transport: a review. Pharmacotherapy 1996; 16: 971–985.PubMedGoogle Scholar
  166. 166.
    O’Reilly RA. Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med 1974; 81: 337–340.CrossRefGoogle Scholar
  167. 167.
    Modry DL, Stinson EB, Oyer PE, et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313–314.PubMedCrossRefGoogle Scholar
  168. 168.
    Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999; 65: 428–438.PubMedCrossRefGoogle Scholar
  169. 169.
    LeBel M, Masson E, Guilbert E, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 1998; 38: 1042–1050.PubMedCrossRefGoogle Scholar
  170. 170.
    Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628–633.PubMedCrossRefGoogle Scholar
  171. 171.
    Jones TE. The use of other drugs to allow a lower dosage of cyclosporine to be used. Therapeutic and pharmacoeconomic considerations. Clin Pharmacokinet 1997; 32: 357–367.PubMedCrossRefGoogle Scholar
  172. 172.
    Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654–660.PubMedGoogle Scholar
  173. 173.
    Caranasos GJ, Stewart RB, Cluff LE. Clinically desirable drug interactions. Ann Rev Pharmacol Toxicol 1985; 25: 67–95.CrossRefGoogle Scholar
  174. 174.
    Pizzo PA. Management of fever in patients with cancer and treatment-induced. N Engl J Med 1993; 328: 1323–1332.PubMedCrossRefGoogle Scholar
  175. 175.
    Eliopoulos GM. The ten most commonly asked questions about resistant enterococcal infections. Infect Dis Clin Pract 1994; 13: 125–129.CrossRefGoogle Scholar
  176. 176.
    Lepper MC, Dowling HF. Treatment of pneumococcal meningitis with penicillin compared with penicillin plus aureomycin. Arch Intern Med 1951; 88: 489–494.CrossRefGoogle Scholar
  177. 177.
    Rice JM, Diwan BA, Ward JM, et al. Phenobarbital and related compounds: approaches to interspecies extrapolation. Prog Clin Biol Res 1992; 374: 231–249.PubMedGoogle Scholar
  178. 178.
    Strolin Benedetti M, Dostert P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994; 102 (suppl 9): 101–105.CrossRefGoogle Scholar
  179. 179.
    Maenpaa J, Hall SD, Ring BJ, et al. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998; 8: 137–155.PubMedGoogle Scholar
  180. 180.
    Guengerich FP. Characterization of human microsomal cytochrome P-450 enzymes. Ann Rev Pharmacol Toxicol 1989; 29: 241–264.CrossRefGoogle Scholar
  181. 181.
    Rodrigues AD. Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 465–480.PubMedCrossRefGoogle Scholar
  182. 182.
    Gonzalez FJ, Korzekwa KR. Cytochromes P450 expression systems. Ann Rev Pharmacol Toxicol 1995; 35: 369–390.CrossRefGoogle Scholar
  183. 183.
    Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Disp 1995; 23: 1339–1346.Google Scholar
  184. 184.
    Fischer V, Vogels B, Maurer G, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260: 1355–1360.PubMedGoogle Scholar
  185. 185.
    Dahl ML, Llerena A, Bondesson U, et al. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71–74.PubMedCrossRefGoogle Scholar
  186. 186.
    Lipp HP, Schrenk D, Wiesmuller T, et al. Assessment of biological activities of mixtures of polychlorinated dibenzo-p-dioxins (PCDDs) and their constituents in human HepG2 cells. Arch Toxicol 1992; 66: 220–223.PubMedCrossRefGoogle Scholar
  187. 187.
    Krusekopf S, Kleeberg U, Hildebrandt AG, et al. Effects of benzimidazole derivatives on cytochrome P450 1A1 expression in a human hepatoma cell line. Xenobiotica 1997; 27: 1–9.PubMedCrossRefGoogle Scholar
  188. 188.
    VandenBranden M, Wrighton SA, Ekins S, et al. Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. Drug Metab Disp 1998; 26: 1063–1068.Google Scholar
  189. 189.
    Dogterom P. Development of a simple incubation system for metabolism studies with precision-cut liver slides. Drug Metab Disp 1993; 21: 699–704.Google Scholar
  190. 190.
    Borchardt RT, Wilson G, Smith P, eds. Model Systems for Biopharmaceutical Assessment of Drug Absorption and Metabolism. New York: Plenum, 1996.Google Scholar
  191. 191.
    LeCluyse EL, Madan A, Forster J, et al. Induction of cytochrome P450 enzymes in primary cultures of human hepatocytes. Drug Metab Dispos 1999, in press.Google Scholar
  192. 192.
    Strom SC, Pisarov LA, Korko K, et al. Use of human hepatocytes to study P450 gene induction. Meth Enzymol 1996; 272: 388–401.PubMedCrossRefGoogle Scholar
  193. 193.
    Li AP, Maurel P, Gomez-Lechon MJ, et al. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chemico-Bio Interact 1997; 107: 5–16.CrossRefGoogle Scholar
  194. 194.
    Buchert E, Woosley RL. Clinical implications of variable antiarrhythmic drug metabolism. Pharmacogenetics 1992; 2: 2–11.PubMedCrossRefGoogle Scholar
  195. 195.
    Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 464–475.PubMedCrossRefGoogle Scholar
  196. 196.
    Brockmoller J, Roots I. Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994; 27: 216–248.PubMedCrossRefGoogle Scholar
  197. 197.
    Scavone JM, Friedman H, Greenblatt DJ. et al. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arzeneimittelforschung 1987; 37: 2–6.Google Scholar
  198. 198.
    von Moltke LL, Greenblatt DJ, Schmider J, et al. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998; 55: 113–122.CrossRefGoogle Scholar
  199. 199.
    Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998; 64: 278–285.PubMedCrossRefGoogle Scholar
  200. 200.
    Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 398–430.CrossRefGoogle Scholar
  201. 201.
    Posicor. Voluntary market withdrawal. Nutley, NJ: Roche Laboratories; June 8, 1998.Google Scholar
  202. 202.
    Food and Drug Administration. FDA Talk Paper Seldane and Generic Terfenadine Withdrawn from Market. Rockville, MD: US Department of Health and Human Services, Public Health Service, February 27, 1998.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Angela D. M. Kashuba
  • Joseph S. BertinoJr.

There are no affiliations available

Personalised recommendations